mRNA and its application

By constructing and delivering mRNA vaccines expressing RHDV1 and RHDV2 VP60 target antigens, the biosafety and adjuvant requirements of existing rabbit plague vaccines have been solved, and efficient immune protection effects have been achieved.

CN119372220BActive Publication Date: 2025-08-08SOUTHWEST UNIVERSITY FOR NATIONALITIES
2 Cites 0 Cited by

Patent Information

Application Number
CN202411594149.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-11-08
Publication Date
2025-08-08
Estimated Expiration
2044-11-08

AI Technical Summary

Technical Problem

The existing rabbit plague vaccine has biosafety problems, high demand for pollutant residues and adjuvants, making it difficult to activate an effective cellular immune response, and the lack of cells that can be used for RHDV culture in vitro hinders the development of vaccines.

Method used

The candidate mRNA expression of RHDV1 and RHDV2 VP60 target antigen was constructed using mRNA technology, and the binding region of VP60 protein encoding was optimized by codons, and the delivery of lipid nanoparticles was used to prepare RHDV1-mRNA and RHDV2-mRNA lipid nanoparticles to form a bivalent vaccine.

Benefits of technology

A high level of humoral immune response and cellular immune response were achieved, which significantly improved the protection against RHDV1 and RHDV2, and had good safety and immune efficacy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention aims to provide mRNA and its application. Based on the gene sequence of the VP60 protein receptor binding region of rabbit hemorrhagic disease virus type 1 and type 2 strains isolated and prevalent in China, candidate mRNA expressing the VP60 target antigen of RHDV1 and RHDV2 was constructed using messenger RNA (mRNA) technology. This mRNA was then used to prepare a third-generation rabbit plague vaccine, which carries the sequence information of the antigenic protein and can be effectively translated into the antigenic protein in the cytoplasm, stimulating both cellular and humoral immune responses. Experiments using this vaccine to immunize rabbits have shown that it can induce high levels of antibodies against RHDV1 and RHDV2, and provides good protection against prevalent isolates of RHDV1 and RHDV2. The vaccine exhibits significant advantages in safety and immune efficacy.
Need to check novelty before this filing date? Find Prior Art